Factors associated with survival in patients with visceral leishmaniasis treated at a reference hospital in northern Minas Gerais - Brazil

被引:0
作者
Martins, Igor Monteiro Lima [1 ,5 ]
de Paula, Alfredo Mauricio Batista [1 ]
Caldeira, Antonio Prates [2 ,5 ]
Oliveira, Lanuza Borges [3 ,5 ]
Fernandes, Luciano Freitas [4 ,5 ]
机构
[1] Univ Estadual Montes Claros, Programa Posgrad Ciencias Saude, Montes Claros, MG, Brazil
[2] Univ Estadual Montes Claros, Dept Saude Mulher & Crianca, Montes Claros, MG, Brazil
[3] Univ Estadual Montes Claros, Dept Enfermagem, Montes Claros, MG, Brazil
[4] Univ Estadual Montes Claros, Hosp Univ Clemente Faria, Montes Claros, MG, Brazil
[5] Ctr Univ UNIFIPMOC, Montes Claros, MG, Brazil
关键词
Leishmaniasis; Visceral; Survival; Prognosis; Public Health; AMPHOTERICIN-B; IN-VITRO; MORTALITY;
D O I
10.1590/0037-8682-0045-2024
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Background: Visceral leishmaniasis (VL) is a public health problem and is a relevant cause of death in developing countries. This study aimed to evaluate the 20 -year survival and predictors of worse prognosis in patients with VL admitted to a reference hospital for the treatment of infectious diseases between 1995 and 2016 in northern Minas Gerais, an area of high endemicity for VL. Methods: This retrospective cohort study was conducted at a hospital in northern Minas Gerais, Brazil. All patients with VL were evaluated over a 20 -year period. The medical records were thoroughly analyzed. Cox regression analysis was performed to estimate factors associated with the probability of survival. Results: The cohort included 972 individuals, mostly male children <10 years old, from urban areas who presented at admission with the classic triad of fever, hepatosplenomegaly, and skin pallor. The mean hemoglobin level was 7.53 mg/dl. The mean interval between symptom onset and hospital admission was 40 days. The instituted therapies ranged from pentavalent antimonates to amphotericin, or both. The probability of survival was reduced to 78% one year after symptom onset. Hemoglobin levels and age were strongly associated with the probability of survival. Conclusions: Regardless of the mechanism underlying the reduction in hemoglobin and the non -modifiable factors of age, early initiation of drug treatment is the most appropriate strategy for increasing survival in patients with VL, which challenges health systems to reduce the interval between the onset of symptoms and hospital admission.
引用
收藏
页数:8
相关论文
共 41 条
[31]  
Organizaao Mundial de Saade (OMS), 2022, Leishmaniose
[32]  
Organizacao Pan-Americana da Saude (OPAS) Organizacao Mundial da Saude (OMS), Cooperacao Tecnica entre o Ministerio da Saude e a Organizacao Pan-Americana da Saude - Leishmaniose Visceral
[33]  
Rezaei R, 2017, IRAN J PARASITOL, V12, P398
[34]   Risk Factors of Inpatients Mortality of Visceral Leishmaniasis, Khartoum State, Sudan [J].
Salih, Omaima Abdel Majeed Mohamed ;
Nail, Abdelsalam M. ;
Modawe, Gad Allah ;
Swar, Mohamed Osman ;
Ahmed, Mohamed H. ;
Khalil, Atif ;
Satti, Abdelsalam Basheir ;
Abuzeid, Nadir .
JOURNAL OF GLOBAL INFECTIOUS DISEASES, 2020, 12 (03) :135-140
[35]   Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial [J].
Sierra Romero, Gustavo Adolfo ;
Costa, Dorcas Lamounier ;
Nery Costa, Carlos Henrique ;
de Almeida, Roque Pacheco ;
de Melo, Enaldo Viera ;
Guimaraes de Carvalho, Silvio Fernando ;
Rabello, Ana ;
de Carvalho, Andrea Lucchesi ;
Sousa, Anastacio de Queiroz ;
Leite, Roberio Dias ;
Lima, Simone Soares ;
Amaral, Thais Alves ;
Alves, Fabiana Piovesan ;
Rode, Joelle .
PLOS NEGLECTED TROPICAL DISEASES, 2017, 11 (06)
[36]   Amphotericin B treatment for Indian visceral leishmaniasis: Conventional versus lipid formulations [J].
Sundar, S ;
Mehta, H ;
Suresh, AV ;
Singh, SP ;
Rai, M ;
Murray, HW .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (03) :377-383
[37]   Antibody and cytokine levels in visceral leishmaniasis patients with varied parasitemia before, during, and after treatment in patients admitted to Arba Minch General Hospital, southern Ethiopia [J].
Tadesse, Dagimawie ;
Abdissa, Alemseged ;
Mekonnen, Mekidim ;
Belay, Tariku ;
Hailu, Asrat .
PLOS NEGLECTED TROPICAL DISEASES, 2021, 15 (08)
[38]  
Universidade Estadual de Montes Claros - UNIMONTES, 2022, Hospital Universitario Clemente de Faria
[39]   Visceral Leishmaniasis Recent Advances in Diagnostics and Treatment Regimens [J].
van Griensven, Johan ;
Diro, Ermias .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2019, 33 (01) :79-+
[40]  
WHO, 2011, WHO TECH REP SER, V959, P1